Strategic Growth Target large cardiology centers and hospital systems currently evaluating or expanding catheter-based ablation programs, highlighting ULTC’s potential to deliver durable VT lesion outcomes and reduce procedure times.

Regulatory & Market</ Leverage CE Marked and U.S. IDE pivotal study status to approach European and American customers with a credible regulatory pathway, emphasizing faster regulatory confidence and market access.

Funding & Expansion Capitalize on recent $19M financing and ongoing fundraising to co-market solutions with partners or distributors, offering bundled incentives for early adopters and idential training programs.

Key Personnel Engage board and executive connections, including the newly appointed CEO and board members, to accelerate strategic partnerships with major device manufacturers and health systems seeking innovative ablation tech.

International Reach Leverage European market entry through CE approval to pursue cross-border opportunities, collaborating with distributors and third-party service providers to scale adoption of the vCLAS catheter and ULTC system.